Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Shire PLC

www.shire.com

Latest From Immco Diagnostics Inc.

Deal Watch: Allergan And Valeant Sign Deals, But Not With Each Other; All Eyes On Pfizer

Allergan finds a white knight in Actavis and Valeant finds a plan B in diagnostics firm Nicox. Meanwhile Pfizer pays $850 million up front to license Merck KGAA’s anti-PD-L1 antibody, in the hopes of catching up in the immuno-oncology space, and BioMarin takes on Prosensa and its Duchenne muscular dystrophy candidate after it was abandoned by GSK.

BioPharmaceutical Deals

Valeant Picks Up Nicox's Diagnostics Unit

Valeant will pay up to $20 million to gain Nicox's diagnostics unit, including a panel for Sjögren’s syndrome and a lab-developed test for age-related macular degeneration.

Deals Shaping The Medical Industry, November 2013

Derived from Strategic Transactions, Elsevier Business Intelligence’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced September through October 2013.

BioPharmaceutical Medical Device

Deals In Depth: June/July 2013

In a regional deal, AstraZeneca licensed rights to FibroGen’s renal candidate in an alliance worth $815 million; Elan finally agreed to an $8.3 billion takeover by Perrigo; biopharma financing totaled $7.1 billion and $2 billion in June and July, respectively, while device fundraising reached $325 million and $316 million in the same months.

BioPharmaceutical Medical Device
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register